Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SCTB35 + lenalidomide versus rituximab + lenalidomide in relapsed/refractory follicular lymphoma
CTR20262021Phase 3Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SCTB35 in follicular lymphoma (FL), sponsored by Sinocelltech Group Limited. Started Jun 2026; status: active.
02
Drugs
SCTB35
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20262021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262021.